Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | CFB | P00751 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 3/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929125 | 0.80 | GAA (0.40) | ALDH1A1KDM4ECFBSMN1; SMN2 | |
| SCHEMBL5929054 | 0.77 | ALDH1A1 (0.38) | ALDH1A1KDM4ESMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL5929304 | 0.75 | MEN1 (0.34) | ALDH1A1KDM4ECFBSMN1; SMN2LMNA | |
| SCHEMBL5928948 | 0.73 | OPRK1 (0.40) | ALDH1A1KDM4ELMNA | |
| SCHEMBL5928908 | 0.73 | POLB (0.38) | ALDH1A1KDM4ECD274LMNA | |
| SCHEMBL5929050 | 0.73 | SLC2A1 (0.40) | ALDH1A1KDM4ECFBLMNAHSD17B10 | |
| SCHEMBL5928938 | 0.72 | KMT2A (0.39) | ALDH1A1KDM4ECFBSMN1; SMN2 | |
| SCHEMBL5929075 | 0.70 | PDCD1 (0.31) | CD274 | |
| SCHEMBL5929248 | 0.70 | KDM4E (0.33) | ALDH1A1KDM4ECD274SMN1; SMN2LMNA | |
| SCHEMBL5929216 | 0.70 | OPRK1 (0.39) | ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | NEUROGEN CORPORATION (US) | 2006-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154917-A1 | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators | C5AR1, C5AR2, C3AR1 | MDM2 2497/4885ALDH1A1 3884/4885KCNH2 2944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.